INDIANAPOLIS, June 4, 2024
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today
that Melissa Seymour will join the
company as executive vice president of Global Quality and member of
the company's Executive Committee, effective July 22, 2024. Seymour currently serves as the
chief quality officer for Bristol Myers Squibb and succeeds
Johna Norton, whose retirement after
34 years of service was announced earlier this year.
"As we expand global capacity to meet demand and support
pipeline growth, we remain committed to ensuring our medicines are
produced to the highest quality standards," said David A. Ricks, Lilly's chair and CEO. "With
more than 25 years of experience and a proven track record of
leading strategic quality initiatives across product lifecycles,
Melissa will further advance our culture of quality, which has been
integral to our success in bringing innovative medicines to people
around the world."
Seymour is recognized as one of the foremost quality leaders in
the pharmaceutical industry. She has held senior leadership roles
at global pharmaceutical companies, including Bristol Myers Squibb
and Biogen, with extended experience at Novo Nordisk and Glaxo
Smith Kline. She has led the development of quality compliance
strategies, implemented quality processes and systems, and
developed talent to ensure the highest level of quality and
compliance in the pharmaceutical industry.
"I am excited to contribute to Lilly's exceptional quality
culture, where patient health and safety remain at the forefront of
our operations," said Seymour. "With the rapid expansion and
promising pipeline at Lilly, maintaining high standards of quality
is paramount and I am thrilled to play a role in shaping the
company's future."
Seymour holds bachelor's degrees in biological sciences and
biochemistry from North Carolina State
University and an executive MBA from Duke University. She also has several
quality-related certifications from the American Society for
Quality, and contributes to the larger industry through
participation on nonprofit boards, including the Parenteral Drug
Association and other consortiums.
Ricks added, "Johna Norton's
positive impact extends to the millions of people who depend on our
medicines every day. We are grateful for her years of excellent
service and contributions, which will continue to benefit Lilly
after her retirement."
About Lilly
Lilly is a medicine company turning science into healing to make
life better for people around the world. We've been pioneering
life-changing discoveries for nearly 150 years, and today our
medicines help more than 51 million people across the globe.
Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges:
redefining diabetes care; treating obesity and curtailing its most
devastating long-term effects; advancing the fight against
Alzheimer's disease; providing solutions to some of the most
debilitating immune system disorders; and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow
us on Facebook, Instagram and LinkedIn. C-LLY
Lilly Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain forward-looking statements
regarding leadership changes and expectations for the future.
All statements other than statements of historical fact are
statements that could be deemed forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. The words
"will", "anticipate" and similar expressions are intended to
identify forward-looking statements. Actual results may differ
materially due to various factors. The following include some but
not all of the factors that could cause actual results or events to
differ materially from those anticipated, including the significant
costs and uncertainties in the pharmaceutical research and
development process, including with respect to the timing and
process of obtaining regulatory approvals; the impact and outcome
of acquisitions and business development transactions and related
costs; the expiration of intellectual property protection for
certain of the company's products and competition from generic
and/or biosimilar products; the company's ability to protect and
enforce patents and other intellectual property; changes in patent
law or regulations related to data package exclusivity; competitive
developments affecting current products and the company's pipeline;
market uptake of recently launched products; information technology
system inadequacies, breaches, or operating failures; unauthorized
access, disclosure, misappropriation, or compromise of confidential
information or other data stored in the company's information
technology systems, networks, and facilities, or those of third
parties with whom the company shares its data; the impact of global
macroeconomic conditions, trade disruptions, disputes, unrest, war,
regional dependencies, or other costs, uncertainties and risks
related to engaging in business globally; unexpected safety or
efficacy concerns associated with the company's products;
litigation, investigations, or other similar proceedings involving
past, current, or future products or commercial activities as the
company is largely self-insured; issues with product supply and
regulatory approvals stemming from manufacturing difficulties,
disruptions, or shortages, including as a result of
unpredictability and variability in demand, labor shortages,
third-party performance, quality, or regulatory actions related to
our facilities; dependence on certain products for a significant
percentage of our total revenue and an increasingly consolidated
supply chain; reliance on third-party relationships and outsourcing
arrangements; the impact of public health outbreaks, epidemics, or
pandemics, such as the COVID-19 pandemic; regulatory changes or
other developments; regulatory actions regarding operations and
products; continued pricing pressures and the impact of actions of
governmental and private payers affecting pricing of, reimbursement
for, and access to pharmaceuticals; devaluations in foreign
currency exchange rates or changes in interest rates and inflation;
changes in tax law, tax rates, or events that differ from the
company's assumptions related to tax positions; asset impairments
and restructuring charges; changes in accounting and reporting
standards promulgated by the Financial Accounting Standards
Board and the Securities and Exchange
Commission (SEC); regulatory compliance problems or government
investigations; and actual or perceived deviation from
environmental-, social-, or governance-related requirements or
expectations. For additional information about the factors that
could cause actual results or events to differ materially from
forward-looking statements, please see the company's latest Form
10-K and subsequent Forms 8-K and 10-Q filed with the SEC. You
should not place undue reliance on forward-looking statements,
which speak only as of the date of this release. Except as is
required by law, the company expressly disclaims any obligation to
publicly release any revisions to forward-looking statements to
reflect events after the date of this release.
Refer
to:
|
Jordan
Bishop; jordan.bishop@lilly.com; (317) 473-5712
(Media)
|
|
Joe
Fletcher; jfletcher@lilly.com; (317) 296-2884
(Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/melissa-seymour-to-join-lilly-as-executive-vice-president-of-global-quality-302162361.html
SOURCE Eli Lilly and Company